Effect of blocking TNF on IL-6 levels and metastasis in a B16-BL6 melanoma mouse model

Anticancer Research

Volumn 17, Issue 3 C, 1997, Pages 2207-2211

  Cubillos, Suzana ^a   Scallon, Bernard ^b   Feldmann, Marc ^c   Taylor, Peter ^a  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^b CENTOCOR INC   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

IL 6; Melanoma; Metastasis; Mouse; TNF antagonist

Indexed keywords

INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MODEL; CONTROLLED STUDY; LUNG METASTASIS; MALE; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD; HUMANS; IMMUNOGLOBULIN CONSTANT REGIONS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LUNG NEOPLASMS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PROTEIN HYBRIDIZATION; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030812192     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N and Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72: 3666-3670, 1975.
2. Fong YM, Tracey KJ, Moldaver LL, Hesse DG, Manogue KB, Kenney JS, Lee AT, Kuo GC, Allison AC and Lowry SF: Antibodies to cachectin tumor necrosis factor reduce interleukin-1-beta and interleukin-6 appearance during lethal bacteremia. J Exp Med 170: 1627-1633, 1989.
3. Helson L, Green S, Carswell EA and Old LJ: Effect of tumour necrosis factor on cultured human melanoma cells. Nature 258: 731-732, 1975.
4. Shimizu Y, Newman W, Yoshida T and Shaw S: Lymphocyte interactions with endothelial cells. Immunol Today 13: 106-112, 1992.
5. Dayer J, Beutler B and Cerami A: Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 162: 2163-2168, 1985.
6. Frater-Schroeder M, Risan W, Hallmann R, Gautschi P and Bohlen P: Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro angiogenic in vivo. Proc Natl Acad Sci USA 84: 5277-5281, 1987.
7. Malik S, Naylor S, East N, Oliff A and Balkwill F: Cells secreting tumor necrosis factor show enhanced metastasis in nude mice. Eur J Cancer 26: 1031-1034, 1990.
8. Balkwill FR: Tumour necrosis factor and cancer. Prog Growth Factor Res 4: 121-137, 1992.
9. Orosz P, Echtenacher B, Falk W, Ruschoff J, Weber D and Mannel D: Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med 177: 1391-1398, 1993.
10. Qin Z, Kruger-Krasagakes S, Kunzendorf U, Hock H, Diamantstein T and Blankenstein T: Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis. J Exp Med 178: 355-360, 1993.
11. Takenawa J, Kaneko Y, Fukumoto M, Fukatsu A, Hirano T, Fukuyama H, Nakayama H, Fujita J and Yoshida O: Enhanced expression of interleukin-6 in primary human renal carcinoma. J Natl Cancer Inst 83: 1668-1672, 1991.
12. Revel M: Antitumour potentials of interleukin-6. Interferons Cytokines 19: 5-8, 1991.
13. Katz A, Shulman L, Porgador A, Revel M, Feldman M and Eisenbach L: Abrogation of B16 melanoma metastases by long-term low-dose interleukin-6 therapy. J Immunother 13: 98-109, 1993.
14. Scallon B, Trinh H, Nedelman M, Brennan F, Feldmann M and Ghrayeb J: Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins. Cytokines 7: 759-770, 1995.
15. Espevik T and Nissen-Meyer J: A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 95: 99-105, 1986.
16. Aarden L, De Groot E, Schaap O and Landsdorp P: Production of hybridoma growth factor by human monocytes. Eur J Immunol 17: 1411-1416, 1987.
17. Mannel D, Janicke R, Westenfelder U, Echtenacher B, Kist A and Falk W: Tumor-induced tumor necrosis factor production in macrophages. Lymphokine Res 9: 485-489, 1990.
18. Theodos C, Povinelli L, Molina R, Sherry B and Titus RL: Role of tumor necrosis factor in macrophage leishmanicidal activity in vitro and resistance to cutaneous leishmaniasis in vivo. Infect Immun 59: 2839-2842, 1991.
19. Orr F, Adamson I and Young L: Promotion of pulmonary metastasis in mice by bleomycin-induced endothelial injury. Cancer Res 46: 891-897, 1986.
20. Spriggs D, Imamura K, Rodriguez C, Sariban E and Kufe D: Tumor necrosis factor expression in human epithelial tumor cell lines. J Clin Invest 81: 455-460, 1988.
21. Hasday J, Shah E and Lieberman A: Macrophage tumor necrosis factor-alpha release is induced by contact with some tumors. J Immunol 145: 371-379, 1990.
22. Balkwill FR, Osborne R, Burke F, Naylor S, Talbot D, Durbin H, Tavernier J and Fiers W: Evidence for tumor necrosis factor/cachectin production in cancer. Lancet 2: 1229-1232, 1987.
23. Naylor S, Malik S, Stamp W, Jobling T and Balkwill F: In situ detection of tumor necrosis factor in human ovarian cancer specimens. Eur J Cancer 26: 1027-1030, 1990.
24. Aderka D, Engelmann H, Hornik V, Skornick Y, Levo Y, Wallach D and Kushtai G: Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 51: 5602-5607, 1991.
25. Evans TJ, Moyes D, Carpenter A, Martin R, Loetscher H, Lesslauer W and Cohen, J: Protective effect of 55- but not 75-kD soluble human tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 180: 2173-2179, 1994.